| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-056 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1999-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2004-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_506f782e984d7215542ac39894f4a72a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3895e682c8a30c9b39d62c9046c7886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b43e87d2e3d6d4d04bfbeafe400fbb59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4a979893eb17109c1ea051588066f7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92337b02dc91346238dca05cbfc36231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e618636647f6e0edd3876c9e5e8b2f8b |
| publicationDate |
2004-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1121369-B1 |
| titleOfInvention |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| abstract |
A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula (I) and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks. |
| priorityDate |
1998-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |